ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Membranous Glomerulonephritis

Kidney Disease trials near Rochester, MN, USA:

A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that caus...

Enrolling
Autosomal Dominant Polycystic Kidney Disease
Drug: ABBV-CLS-628
Drug: Placebo

Phase 2

AbbVie
AbbVie

Rochester, Minnesota, United States and 46 other locations

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Rochester, Minnesota, United States and 17 other locations

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease (PIONEER-PKD)

and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney...

Not yet enrolling
Autosomal Dominant Polycystic Kidney Disease
Drug: Placebo - Part B
Drug: Placebo - Part A

Phase 1

AstraZeneca
AstraZeneca

Rochester, Minnesota, United States and 10 other locations

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney...

Active, not recruiting
Anemia of Chronic Kidney Disease
Chronic Kidney Diseases
Drug: DISC-0974
Drug: Placebo

Phase 1

Disc Medicine

Rochester, Minnesota, United States and 11 other locations

A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)

To evaluate the safety of tolvaptan in pediatric subjects with ARPKD

Enrolling
Autosomal Recessive Polycystic Kidney (ARPKD)
Drug: Tolvaptan Tablets
Drug: Tolvaptan Suspension

Phase 3

Otsuka
Otsuka

Rochester, Minnesota, United States and 22 other locations

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease...

Active, not recruiting
Kidney Diseases
Diagnostic Test: Renasight
Natera
Natera

Rochester, Minnesota, United States and 30 other locations

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.

Enrolling
X-linked Hypophosphatemia
Drug: KK8123

Phase 1, Phase 2

Kyowa Kirin
Kyowa Kirin

Rochester, Minnesota, United States and 8 other locations

Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3)

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-...

Active, not recruiting
Kidney Diseases
Genetic Disease
Drug: DCR-PHXC

Phase 3

Dicerna Pharmaceuticals

Rochester, Minnesota, United States and 22 other locations

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

efficacy assessments conducted every 6 months will afford the opportunity to evaluate the clinical effects of iptacopan on long-term disease...

Enrolling
Primary IgA Nephropathy
Drug: LNP023

Phase 3

Novartis
Novartis

Rochester, Minnesota, United States and 146 other locations

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD (POSITANO)

PLD (ADPLD) or associated with autosomal dominant polycystic kidney disease (ADPKD).In the Treatment Period of the trial, participa...

Active, not recruiting
Polycystic Liver Disease
Drug: Placebo
Drug: CAM2029

Phase 2, Phase 3

Camarus

Rochester, Minnesota, United States and 10 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems